https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-08-22 / Blood 2017 10;130(15):1713-1721
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-08-22 / Blood 2017 10;130(15):1713-17212017-08-22 00:00:002019-02-15 08:32:49Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-07-25 / J Hematol Oncol 2017 07;10(1):142
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-07-25 / J Hematol Oncol 2017 07;10(1):1422017-07-25 00:00:002019-02-15 08:32:50Recent developments in immunotherapy of acute myeloid leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-28 / J. Therm. Biol. 2017 Jul;67:9-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-28 / J. Therm. Biol. 2017 Jul;67:9-142017-04-28 00:00:002019-02-15 08:32:53Hyperthermia enhances bortezomib-induced apoptosis in human white blood cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-14 / Cancer 2017 Aug;123(16):3061-3072
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-14 / Cancer 2017 Aug;123(16):3061-30722017-04-14 00:00:002019-02-15 08:32:48Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-07 / Sci Transl Med 2016 12;8(368):368ra171
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-07 / Sci Transl Med 2016 12;8(368):368ra1712016-12-07 00:00:002019-02-15 08:32:47Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-09-12 / Biol. Blood Marrow Transplant. 2016 12;22(12):2149-2154
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-09-12 / Biol. Blood Marrow Transplant. 2016 12;22(12):2149-21542016-09-12 00:00:002019-02-15 08:32:47Induction of Immune Response after Allogeneic Wilms‘ Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-09 / Expert Opin Biol Ther 2016 09;16(9):1113-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-09 / Expert Opin Biol Ther 2016 09;16(9):1113-232016-06-09 00:00:002019-02-15 08:32:44Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 7007)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 7007)2015-05-30 00:00:002021-08-09 07:52:34Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-22 / Br. J. Haematol. 2015 May;169(3):356-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-22 / Br. J. Haematol. 2015 May;169(3):356-672015-01-22 00:00:002019-02-15 08:45:29Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3125-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(11):3125-312014-01-01 00:00:002019-02-15 08:32:45Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies
